Evidence map›Paper›PMID 37351600›Full record

ReviewDermatologie (Heidelberg, Germany)2023

[Fluorescence detection to diagnose melanoma : An alternative objective method for dermatohistology].

Dieter Leupold

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Dermatologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Dieter Leupoldvormals LTB Lasertechnik Berlin GmbH, Am Studio 2c, 12489, Berlin, Deutschland. dieter.e.leupold@web.de.
Laser- und Medizin-Technologie (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDermatohistological assessment is the gold standard in the diagnosis of melanoma. As a subjective method, this depends, among other things, on the expertise of the examiner.

aimA new objective method of investigation-dermatohistofluoroscopy-aims to improve the diagnostic reliability of melanoma diagnosis. MATERIALS AND

methodsThe ultra-weak spectrally resolved fluorescence of melanin of pigment-bearing skin cells is a reliable indicator of the malignancy of the tissue to be diagnosed. Using a special laser spectroscopic method, this fluorescence can be measured on histological specimen (and also on tissue in vivo and on excidate). RESULTS AND DISCUSSION: Melanocytes from normally pigmented skin, nevomelanocytes from benign and dysplastic nevi, and melanoma cells each show characteristic, different fluorescence spectra. If these cell types are shown spatially resolved in different colors on the preparation to be diagnosed, they give the histologist an objective basis for the diagnosis, even in difficult cases, e.g., the so-called stumbling blocks of melanoma diagnosis such as Spitzoid tumors. Currently, the method can only be used for Fitzpatrick skin types 1 and 2. In addition, a separate second measurement signal at 400 nm can be used to identify tumor breakthrough through the basement membrane. This signal is collagen bound, so it also appears in amelanotic melanomas, to which the method is otherwise inherently inapplicable.

Indexed as

Melanoma, AmelanoticSkin NeoplasmsHumansMelanocytesReproducibility of ResultsSkinDermatohistofluoroscopyDiagnostic reliabilityEccentric tumor positionPagetoid spreadSpitzoid nevi and neoplasms

Identifiers

PMID37351600
OpenAlexW4381716649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.